ORIC PHARMACEUTICALS INC's ticker is ORIC and the CUSIP is 68622P109. A total of 72 filers reported holding ORIC PHARMACEUTICALS INC in Q1 2023. The put-call ratio across all filers is 0.72 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $20,679,311 | -22.0% | 3,418,068 | 0.0% | 0.70% | +7.4% |
| Q2 2023 | $26,524,208 | +36.1% | 3,418,068 | 0.0% | 0.65% | +3.7% |
| Q1 2023 | $19,482,988 | -3.2% | 3,418,068 | 0.0% | 0.63% | +2.3% |
| Q4 2022 | $20,132,421 | +84.1% | 3,418,068 | 0.0% | 0.61% | +89.8% |
| Q3 2022 | $10,938,000 | -28.6% | 3,418,068 | 0.0% | 0.32% | -38.9% |
| Q2 2022 | $15,313,000 | -16.1% | 3,418,068 | 0.0% | 0.53% | -7.4% |
| Q1 2022 | $18,252,000 | -64.2% | 3,418,068 | -1.5% | 0.57% | -64.9% |
| Q4 2021 | $50,993,000 | -29.7% | 3,468,944 | 0.0% | 1.62% | -35.6% |
| Q3 2021 | $72,536,000 | +32.6% | 3,468,944 | +12.2% | 2.52% | +23.4% |
| Q2 2021 | $54,701,000 | -27.8% | 3,092,218 | 0.0% | 2.04% | -39.2% |
| Q1 2021 | $75,759,000 | -27.6% | 3,092,218 | 0.0% | 3.36% | -40.3% |
| Q4 2020 | $104,672,000 | +58.4% | 3,092,218 | +17.0% | 5.63% | +19.4% |
| Q3 2020 | $66,082,000 | -25.9% | 2,642,218 | 0.0% | 4.71% | -28.4% |
| Q2 2020 | $89,122,000 | – | 2,642,218 | – | 6.58% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Column Group LLC | 4,768,181 | $161,403,000 | 14.64% |
| Invus Financial Advisors, LLC | 1,007,575 | $34,106,000 | 14.26% |
| Euclidean Capital LLC | 1,400,435 | $47,405,000 | 10.04% |
| Memorial Sloan Kettering Cancer Center | 602,272 | $20,387,000 | 8.63% |
| EcoR1 Capital, LLC | 3,092,218 | $104,672,000 | 5.63% |
| Ally Bridge Group (NY) LLC | 413,061 | $13,982,000 | 2.40% |
| Asymmetry Capital Management, L.P. | 67,210 | $2,275,000 | 1.04% |
| Orbimed Advisors | 2,921,967 | $98,909,000 | 0.86% |
| Casdin Capital, LLC | 601,515 | $20,361,000 | 0.60% |
| EMERALD ADVISERS, LLC | 522,302 | $17,680,000 | 0.59% |